by Plus Therapeutics | Nov 8, 2024 | LM
You’re Invited to our symposium “Novel Targeted Radiotherapies to Manage Leptomeningeal Metastases,” presented at the Society for Neuro-Oncology Annual meeting in Houston. More information & RSVP: https://forms.gle/4WYXhAQzb7LHbpTm9 Don’t...
by Plus Therapeutics | Oct 29, 2024 | LM
Mark your calendars: We will be showcasing our Leptomeningeal Metastases programs at the 2024 SNO Annual Meeting in Houston, Texas! Plus Therapeutics will present data from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal...
by Plus Therapeutics | Oct 2, 2024 | LM
COMING SOON 🎗️💓 In honor of #BreastCancerAwarenessMonth, we are excited to announce that we will be sharing a patient testimonial from one of our Metastatic Breast Cancer patients who was treated for Leptomeningeal Metastases through the ReSPECT-LM Clinical Trial. She...
by Plus Therapeutics | Aug 12, 2024 | LM
Highlights include: > Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda > High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to...
by Plus Therapeutics | Jun 27, 2024 | LM
❗NEW CLINICAL TRIAL INVESTIGATION SITE❗ We are pleased to announce the addition of Ohio State University in Columbus, Ohio to our ReSPECT-LM Clinical Trial with Principal Investigator Shirley Ong M.D.. This site is NOW ENROLLING patients. Learn More about Dr. Ong:...
by Plus Therapeutics | Jun 19, 2024 | LM
June is Brain & Spine Metastasis Awareness Month! 🧠🎗️ We want to continue to raise awareness for Leptomeningeal Metastases, which is diagnosed in approximately 110,000 cases per year in the U.S. Learn more about this metastatic cancer by visiting our Comprehensive...
Recent Comments